Co-Authors
This is a "connection" page, showing publications co-authored by Nathaniel Baker and Rachel Tomko.
Connection Strength
2.032
-
Characterization of Salivary Progesterone in Female Smokers. Nicotine Tob Res. 2022 10 26; 24(11):1829-1833.
Score: 0.216
-
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.201
-
Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. Addict Biol. 2021 03; 26(2):e12918.
Score: 0.183
-
Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. Nicotine Tob Res. 2020 01 27; 22(1):81-88.
Score: 0.179
-
Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges. Curr Addict Rep. 2019 Dec; 6(4):429-436.
Score: 0.177
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.176
-
Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol. 2019 12; 30:35-41.
Score: 0.167
-
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.153
-
Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology (Berl). 2017 Feb; 234(3):427-435.
Score: 0.143
-
Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial. BMC Psychol. 2023 Jan 25; 11(1):25.
Score: 0.055
-
Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug Alcohol Depend. 2021 08 01; 225:108815.
Score: 0.049
-
Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine Tob Res. 2020 07 16; 22(8):1374-1382.
Score: 0.046
-
Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. Psychoneuroendocrinology. 2020 10; 120:104752.
Score: 0.046
-
The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. Psychopharmacology (Berl). 2020 Feb; 237(2):543-555.
Score: 0.044
-
Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatr. 2019 12 01; 173(12):1146-1153.
Score: 0.044
-
Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
Score: 0.041
-
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
Score: 0.039
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.037
-
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
Score: 0.035